Secondary Cancers after Chimeric Antigen Receptor T-Cell Therapy
Nicole Verdun, Peter Marks
Abstract
As of December 31, 2023, the FDA had become aware of 22 cases of T-cell cancers that occurred after treatment with CAR-T products. For now, such cancers appear to be relatively rare adverse events.
Topics & Concepts
Chimeric antigen receptorMedicineAdverse effectAntigenReceptorCancer researchOncologyImmunotherapyImmunologyInternal medicineCancerCAR-T cell therapy researchBiomedical Ethics and RegulationBiomedical and Engineering Education